IDEXX’s Post

It’s rare to be part of something that has the potential to dramatically improve the lives of thousands of pets. If we’re lucky, it may happen once or twice in a career. I have been fortunate to be a part of several such innovations at IDEXX – but I believe this one has the potential to be particularly historic. It is with tremendous pride and gratitude to the IDEXX team and their achievement that today I share with you the news that we’ve launched IDEXX Cancer Dx™ through our reference laboratories in North America. This first-of-its-kind diagnostic panel for early detection of canine lymphoma brings exceptional levels of performance (79% sensitivity, 99% specificity), turnaround time in as few as 2 to 3 days, and is priced for our veterinarian partners in a way that is intended to support broad inclusion and access to pet owners. This is the culmination of years of scientific exploration, teamwork, and novel approaches to the field of cancer research and diagnostics. The earlier we can detect cancer and determine its type, the better the chance for targeted treatments and improved outcomes, such as additional quality months or years of life. For many of us, cancer is personal. Our family dog, Blake, died too soon last year from lung cancer. We know too well how hard it is to detect and treat at later stages. IDEXX does not plan to stop with canine lymphoma. Instead, over the next 36 months, we plan to launch a panel that will cover a majority (>50%) of canine cancer cases. My gratitude goes out to all veterinary practices worldwide who work passionately every day to advance the standard of care for the animals we love. We couldn’t be prouder to partner with you on this endeavor. idexx.com/cancerdx